Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755040 · ClinicalTrials.gov registry record · Phase 3
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
A Phase 3 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 164
- Enrollment target
NCT00755040 is a Phase 3 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 164 participants.
The verdict
NCT00755040, a Phase 3 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 164 participants
- Enrollment target
Study Summary
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder. PURPOSE: This randomized phase I trial is studying how well cyclosporine eye drops work in preventing graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
Interventions
- OTHER placebo
- DRUG cyclosporine ophthalmic emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2008-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00755040
The ClinicalTrials.gov registry entry for NCT00755040 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00755040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00755040 about?
NCT00755040 is a clinical study titled "Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder". RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder. PURPOSE: This randomized phase I trial is studying how well cyclosporine eye drops work in preventing ...
What is the current status of trial NCT00755040?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 164 participants. The study started on 2008-10. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00755040?
The interventions under investigation include: placebo (OTHER), cyclosporine ophthalmic emulsion (DRUG).
Who is sponsoring clinical trial NCT00755040?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.